公开(公告)号：US20220002278A9

公开(公告)日：2022-01-06

申请号：US17075206

申请日：2020-10-20

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Cheng Luo ,  Hualiang Jiang ,  Yaxi Yang ,  Lianghe Mei ,  Wenchao Lu ,  Senhao Xiao ,  Shijie Chen ,  Shili Wan ,  Gang Qiao ,  Rukang Zhang

IPC分类号： C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10

摘要： Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

公开(公告)号：US20240059676A1

公开(公告)日：2024-02-22

申请号：US18267298

申请日：2021-12-10

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Ying Leng ,  Yaxi Yang ,  Mengmeng Ning ,  Liuyu Hu ,  Lei Feng ,  Ju Liang

IPC分类号： C07D403/10 ,  C07D413/10 ,  C07D471/04 ,  A61P3/06

CPC分类号： C07D403/10 ,  C07D413/10 ,  C07D471/04 ,  A61P3/06

摘要： The present invention relates to a thyroid hormone receptor β selective agonist compound represented by formula I, a pharmaceutical composition and use thereof. The compound improves the selectivity to THR-α and the druggability of the compound while maintaining good THR-β agonistic activity, and shows a certain activity in in vivo pharmacological experiments.

公开(公告)号：US20210101891A1

公开(公告)日：2021-04-08

申请号：US17075206

申请日：2020-10-20

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENC

发明人： Bing Zhou ,  Cheng Luo ,  Hualiang Jiang ,  Yaxi Yang ,  Lianghe Mei ,  Wenchao Lu ,  Senhao Xiao ,  Shijie Chen ,  Shili Wan ,  Gang Qiao ,  Rukang Zhang

IPC分类号： C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10

摘要： Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

公开(公告)号：US11427593B2

公开(公告)日：2022-08-30

申请号：US16962347

申请日：2019-01-11

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing Zhou ,  Cheng Luo ,  Zizhou Li ,  Yaxi Yang ,  Shijie Chen ,  Hong Ding ,  Hualiang Jiang ,  Gang Qiao ,  Xinjun Wang ,  Senhao Xiao

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61P35/02

摘要： The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.

公开(公告)号：US12065447B2

公开(公告)日：2024-08-20

申请号：US18045149

申请日：2022-10-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

公开(公告)号：US11498927B2

公开(公告)日：2022-11-15

申请号：US17289642

申请日：2019-10-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

公开(公告)号：US20230167129A1

公开(公告)日：2023-06-01

申请号：US18045149

申请日：2022-10-08

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： Bing Zhou ,  Wei Tang ,  Xiangbo Yang ,  Huimin Lu ,  Mengying Gao ,  Yaxi Yang ,  Huijin Feng

IPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

CPC分类号： C07D513/04 ,  A61P37/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

摘要： The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.

公开(公告)号：US11013745B2

公开(公告)日：2021-05-25

申请号：US16651510

申请日：2018-08-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing Zhou ,  Cheng Luo ,  Yaxi Yang ,  Yuanyuan Zhang ,  Daohai Du ,  Hualiang Jiang ,  Gang Qiao ,  Xinjun Wang

IPC分类号： A61K31/519 ,  C07D487/04

摘要： The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.